急性髓系白血病的靶向治疗药物研发进展

Progress in Development of Targeted Therapeutic Drugs for Acute Myeloid Leukemia

摘要: 在过去的十年里，急性髓系白血病（AML）的靶向治疗药物研发呈现出井喷式的势头，为AML患者的精准治疗奠定了坚实的基础。本文综述了近期在AML治疗领域进展较快的4类靶向药物（靶向基因或信号通路改变、靶向细胞凋亡相关通路、靶向细胞表面抗原以及靶向免疫相关靶点），并展望了未来靶向药物的开发方向，为血液科医师和AML新药开发人员提供参考。

Abstract: Targeted therapeutic drugs for acute myeloid leukemia (AML) are showing immense development, thereby laying a solid foundation for the precise treatment of AML patients. The paper reviews four types of targeted drugs that have progressed rapidly for AML treatment (by targeting genes or signaling-pathway alterations, targeting apoptosis-related pathways, targeting cell-surface antigens, and targeting immune-related substances). We look forward to the future development directions of targeted drugs, providing references for hematologists and developers of new drugs for AML.